annual FCF:
$182.80M+$253.64M(+358.02%)Summary
- As of today (July 1, 2025), PTGX annual free cash flow is $182.80 million, with the most recent change of +$253.64 million (+358.02%) on December 31, 2024.
- During the last 3 years, PTGX annual FCF has risen by +$291.76 million (+267.76%).
- PTGX annual FCF is now at all-time high.
Performance
PTGX Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$124.82M+$154.31M(+523.28%)Summary
- As of today (July 1, 2025), PTGX quarterly free cash flow is $124.82 million, with the most recent change of +$154.31 million (+523.28%) on March 1, 2025.
- Over the past year, PTGX quarterly FCF has increased by +$152.49 million (+551.08%).
- PTGX quarterly FCF is now -53.53% below its all-time high of $268.59 million, reached on June 30, 2024.
Performance
PTGX quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$335.29M+$152.49M(+83.42%)Summary
- As of today (July 1, 2025), PTGX TTM free cash flow is $335.29 million, with the most recent change of +$152.49 million (+83.42%) on March 1, 2025.
- Over the past year, PTGX TTM FCF has increased by +$399.44 million (+622.59%).
- PTGX TTM FCF is now at all-time high.
Performance
PTGX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
PTGX Free cash flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +358.0% | +551.1% | +622.6% |
| 3 y3 years | +267.8% | +429.0% | +384.1% |
| 5 y5 years | +530.2% | +880.8% | +607.7% |
PTGX Free cash flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +267.8% | -53.5% | +463.3% | at high | +380.6% |
| 5 y | 5-year | at high | +267.8% | -53.5% | +429.0% | at high | +380.6% |
| alltime | all time | at high | +267.8% | -53.5% | +429.0% | at high | +380.6% |
PTGX Free cash flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $124.82M(-523.3%) | $335.29M(+83.4%) |
| Dec 2024 | $182.80M(-358.0%) | -$29.49M(+3.0%) | $182.80M(-20.3%) |
| Sep 2024 | - | -$28.64M(-110.7%) | $229.23M(-0.7%) |
| Jun 2024 | - | $268.59M(-1070.7%) | $230.85M(-459.8%) |
| Mar 2024 | - | -$27.67M(-263.3%) | -$64.16M(-9.4%) |
| Dec 2023 | -$70.84M(-35.0%) | $16.94M(-162.7%) | -$70.84M(-40.7%) |
| Sep 2023 | - | -$27.02M(+2.3%) | -$119.49M(+1.4%) |
| Jun 2023 | - | -$26.41M(-23.1%) | -$117.84M(+11.9%) |
| Mar 2023 | - | -$34.36M(+8.4%) | -$105.35M(-3.3%) |
| Dec 2022 | -$108.93M(-0.0%) | -$31.70M(+25.0%) | -$108.93M(+4.4%) |
| Sep 2022 | - | -$25.36M(+82.1%) | -$104.36M(-3.1%) |
| Jun 2022 | - | -$13.93M(-63.3%) | -$107.73M(-8.7%) |
| Mar 2022 | - | -$37.94M(+39.8%) | -$118.01M(+8.3%) |
| Dec 2021 | -$108.97M(+49.4%) | -$27.14M(-5.6%) | -$108.97M(+8.1%) |
| Sep 2021 | - | -$28.73M(+18.7%) | -$100.82M(+14.0%) |
| Jun 2021 | - | -$24.20M(-16.3%) | -$88.45M(+3.0%) |
| Mar 2021 | - | -$28.90M(+52.1%) | -$85.86M(+17.7%) |
| Dec 2020 | -$72.95M(+71.7%) | -$18.99M(+16.1%) | -$72.95M(+6.6%) |
| Sep 2020 | - | -$16.36M(-24.3%) | -$68.47M(+3.7%) |
| Jun 2020 | - | -$21.61M(+35.2%) | -$66.05M(+58.6%) |
| Mar 2020 | - | -$15.99M(+10.2%) | -$41.65M(-2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$42.49M(-15.7%) | -$14.51M(+4.1%) | -$42.49M(+11.3%) |
| Sep 2019 | - | -$13.94M(-601.7%) | -$38.18M(+13.4%) |
| Jun 2019 | - | $2.78M(-116.5%) | -$33.67M(-35.1%) |
| Mar 2019 | - | -$16.83M(+65.0%) | -$51.91M(+2.9%) |
| Dec 2018 | -$50.43M(-1673.1%) | -$10.20M(+8.2%) | -$50.43M(-7.4%) |
| Sep 2018 | - | -$9.42M(-39.1%) | -$54.44M(+1109.0%) |
| Jun 2018 | - | -$15.47M(+0.8%) | -$4.50M(+159.4%) |
| Mar 2018 | - | -$15.35M(+8.0%) | -$1.74M(-154.1%) |
| Dec 2017 | $3.21M(-110.6%) | -$14.21M(-135.1%) | $3.21M(-58.2%) |
| Sep 2017 | - | $40.51M(-419.0%) | $7.68M(-119.3%) |
| Jun 2017 | - | -$12.70M(+22.1%) | -$39.83M(+13.1%) |
| Mar 2017 | - | -$10.40M(+6.9%) | -$35.23M(+16.2%) |
| Dec 2016 | -$30.32M(+105.1%) | -$9.73M(+39.1%) | -$30.32M(+18.7%) |
| Sep 2016 | - | -$7.00M(-13.6%) | -$25.55M(+13.9%) |
| Jun 2016 | - | -$8.10M(+47.6%) | -$22.43M(+25.8%) |
| Mar 2016 | - | -$5.49M(+10.7%) | -$17.84M(+20.6%) |
| Dec 2015 | -$14.78M(+83.8%) | -$4.96M(+27.7%) | -$14.78M(+50.5%) |
| Sep 2015 | - | -$3.88M(+10.8%) | -$9.82M(+65.3%) |
| Jun 2015 | - | -$3.50M(+43.8%) | -$5.94M(+143.8%) |
| Mar 2015 | - | -$2.44M | -$2.44M |
| Dec 2014 | -$8.04M | - | - |
FAQ
- What is Protagonist Therapeutics annual free cash flow?
- What is the all time high annual FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual FCF year-on-year change?
- What is Protagonist Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly FCF year-on-year change?
- What is Protagonist Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM FCF year-on-year change?
What is Protagonist Therapeutics annual free cash flow?
The current annual FCF of PTGX is $182.80M
What is the all time high annual FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual free cash flow is $182.80M
What is Protagonist Therapeutics annual FCF year-on-year change?
Over the past year, PTGX annual free cash flow has changed by +$253.64M (+358.02%)
What is Protagonist Therapeutics quarterly free cash flow?
The current quarterly FCF of PTGX is $124.82M
What is the all time high quarterly FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly free cash flow is $268.59M
What is Protagonist Therapeutics quarterly FCF year-on-year change?
Over the past year, PTGX quarterly free cash flow has changed by +$152.49M (+551.08%)
What is Protagonist Therapeutics TTM free cash flow?
The current TTM FCF of PTGX is $335.29M
What is the all time high TTM FCF for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM free cash flow is $335.29M
What is Protagonist Therapeutics TTM FCF year-on-year change?
Over the past year, PTGX TTM free cash flow has changed by +$399.44M (+622.59%)